Best Pharma Strategies from the Experts

The challenges healthcare executives and administrators face are constantly changing. Host Kevin Stevenson talks with the heroes behind the heroes that are enabling hospitals, urgent care centers and telemedicine operators to spend their time tending to patients, while they handle the logistics.

 

At one point in his career, I Don’t Care Host Kevin Stevenson spent some time on the pharma side of things, in between working at hospitals.

Today he dives back into that world with Donovan Quill, President, and CEO at Optime Care, a nationally recognized pharmacy, distribution, and patient management organization that creates the trusted path to a fulfilled life for patients with rare and orphan disorders.

“What we try to do is create a holistic program for those patients where we combine all the services you would see in a pharmacy in a patient care model,” Quill said. “We try to create a one-stop-shop for patients to really get the care they need from a support standpoint, from affordability, and also to distribute their products to them in their home or site of care.”

“Our patient populations we treat here at Optime care range from 16 patients nationwide all the way up to a couple of thousand.” – Donovan Quill

Orphan disorders and drugs are a bit different from regular pharmaceuticals. Typically, an orphan drug is a treatment for a condition with less than 200,000 patients in the U.S., according to the FDA definition. But, what they do at Optime Care is treat disorders that are even more rare, or “Ultra orphan,” according to Quill.

“Our patient populations we treat here at Optime care range from 16 patients nationwide all the way up to a couple of thousand,” Quill said. “We really try to focus on the patients who need a little extra care.”

Most of the time, the patients they treat have a disorder they’ve never heard of and are treated with a product they can’t pronounce, Quill said jokingly.

Listen to Previous Episodes of I Don’t Care!

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

Rothman Index
The Origin Story of the Rothman Index – Episode 5
January 8, 2026

Hospitals collect enormous amounts of clinical data, yet preventable patient decline remains a persistent challenge. Over the past two decades, hospitals have invested heavily in early warning scores and rapid response infrastructure, but translating data into timely, meaningful action has proven difficult. As clinicians contend with alert fatigue and increasing documentation burden, a more…

Read More
Rothman Index
My Mother and the Story of the Genesis of the Rothman Index – Episode 4
January 8, 2026

Healthcare generates enormous volumes of clinical data, yet making sense of that information in real time remains a challenge. Subtle changes in vitals, labs, and nursing assessments often precede serious events, but when that information is fragmented across the medical record, emerging risks can go unnoticed. The central challenge facing hospitals today is not…

Read More
home
Delivering Moments That Matter: The Art of Joy, Memory, and Meaning at Anthropologie Home
January 8, 2026

These days, ‘home’ means more than just four walls. It’s where people reset, gather, and express who they are—raising the bar for what they expect from the brands that help shape those spaces. Consumers are no longer just buying décor—they’re investing in meaning, memory, and moments that last. Research continues to show that people…

Read More
Texas energy
Small Margins, Big Risks: How Fraud Hurts Texas Energy Retailers
January 6, 2026

Fraud has quietly become one of the most existential threats in Texas’s deregulated retail electricity market—because the business runs on razor-thin margins and delayed payment. Under the non-POR system overseen by the Electric Reliability Council of Texas (ERCOT), retail energy providers assume the full risk of nonpayment. With profit margins often measured in just a…

Read More